leisure time -WSS

leisure time

author：hotspot 2025-09-29 21:14:38 - browse：2188

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： How AI helped researchers track recovery from depression

leisure time

WSS

The White House hikes tariffs on plastic syringes made in China

How Vertex's cystic fibrosis drug is changing patients' lives

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Obesity drug from Roche shows promise in early study

Second xenotransplant done with gene

Microbiome research is starting to find links to chronic diseases

Wikipedia

leisure time

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Continuity nursing helped my family in our darkest PICU moments

CVS is willing to dump 10% of its Medicare Advantage members

Sports medicine is finally prioritizing gender equality

Abbott's new stent may help patients with peripheral artery disease

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ripples from Flovent's discontinuation is killing children with asthma

Guidelines to prevent youth baseball injuries need more muscle

Novo Nordisk testing Wegovy against alcohol

hotspot

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

CommonSpirit Health keeps growing, even as it loses money

Senators: Long

What a koala virus tells us about the human genome

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

FDA panel to weigh approval of NurOwn, controversial ALS drug

hotspot

focus

leisure time

focus